List of Excipients in Branded Drug 3M SOLUPREP S

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Solventum US LLC	3M SOLUPREP S	chlorhexidine gluconate and isopropyl alcohol	17518-082	ACETYLTRIBUTYL CITRATE	2026-01-20
Solventum US LLC	3M SOLUPREP S	chlorhexidine gluconate and isopropyl alcohol	17518-082	FD&C BLUE NO. 1	2026-01-20
Solventum US LLC	3M SOLUPREP S	chlorhexidine gluconate and isopropyl alcohol	17518-082	FD&C YELLOW NO. 5	2026-01-20
Solventum US LLC	3M SOLUPREP S	chlorhexidine gluconate and isopropyl alcohol	17518-082	TRISODIUM HEDTA	2026-01-20

3M SoluPrep S Excipient Strategy, Formulation IP and Commercial Opportunities

Last updated: October 2, 2026

3M SoluPrep S is a topical surgical skin-preparation product based on 2% chlorhexidine gluconate and 70% isopropyl alcohol. Its formulation is commercially effective because the active system combines rapid alcohol kill with the residual antimicrobial activity of chlorhexidine. The main excipient opportunity is not to add pharmacologically active ingredients. It is to improve skin tolerability, drying behavior, residue, packaging compatibility, applicator performance, and environmental profile while preserving the validated antimicrobial performance of the reference formulation.

The product is better analyzed as a topical antiseptic drug-device combination than as a conventional pharmaceutical drug. Isopropyl alcohol and chlorhexidine gluconate are active antiseptic ingredients. Water is the principal vehicle. Any additional formulation component, such as a colorant, surfactant, emollient, or skin-conditioning agent, must be justified against antimicrobial efficacy, flammability, stability, sterility, and regulatory requirements.

What is 3M SoluPrep S and what are its active ingredients?

3M SoluPrep S is a surgical skin-preparation solution containing 2% chlorhexidine gluconate and 70% isopropyl alcohol. Product presentations typically use a single-use applicator to control dose, reduce contamination risk, and support standardized application before invasive procedures.

Product attribute	SoluPrep S profile
Product category	Topical surgical antiseptic
Primary use	Preoperative skin preparation
Chlorhexidine concentration	2% w/v chlorhexidine gluconate
Isopropyl alcohol concentration	70% v/v
Dosage form	Liquid solution delivered through a single-use applicator
Principal vehicle	Water
Route	Topical
Delivery system	Unit-dose applicator
Key performance requirements	Broad antimicrobial activity, rapid drying, residual activity, low residue, applicator control
Main safety constraints	Flammability, ocular and mucosal exposure, neonatal exposure, skin irritation, alcohol vapor

The formulation aligns with the dominant commercial concentration used for alcohol-based chlorhexidine surgical preparations. FDA materials identify chlorhexidine gluconate and alcohol-based antiseptic products as important healthcare antiseptic categories, while product labeling governs concentration, application, drying, flammability, and exposure warnings.[1][2]

What excipients are used in 3M SoluPrep S?

Public product information identifies the core formulation as an aqueous alcohol solution containing chlorhexidine gluconate and isopropyl alcohol. Water functions as the vehicle. The product may also include presentation-specific components such as a colorant, depending on the market and SKU. The precise composition should be assessed against the applicable country-specific label and technical dossier.

Component	Functional role	Strategic assessment
Chlorhexidine gluconate	Antimicrobial active	Determines residual activity, compatibility, and antimicrobial claims
Isopropyl alcohol	Rapid antimicrobial active and volatile solvent	Drives drying, flammability, odor, and skin-drying effects
Purified water	Vehicle and concentration-control medium	Affects density, assay, evaporation profile, and microbial control
Colorant, if present	Application visibility	Can improve coverage but increases impurity, staining, and regulatory burden
Optional emollient or humectant	Skin-conditioning function	May improve tolerability but can slow drying or reduce antimicrobial performance
Optional surfactant	Wetting and spreading	May improve coverage but can alter skin irritation and chlorhexidine availability

The commercial formulation has a narrow excipient window. A conventional cream, gel, oil, or high-load polymer system would conflict with the product’s rapid-drying and low-residue positioning. The most defensible strategy is a low-complexity formulation with a small number of excipients selected for a measurable performance advantage.

Which excipients offer the strongest commercial opportunity?

The strongest opportunities involve skin tolerance, application control, and environmental performance.

Skin-conditioning excipients

Alcohol can produce dryness, stinging, and irritation, particularly with repeated healthcare-worker exposure or application to compromised skin. Candidate excipients include low-level humectants, polyols, and skin-conditioning agents. Suitable candidates must remain soluble in the hydroalcoholic system and must not leave a persistent film.

Potential candidates include:

• Glycerol or low-molecular-weight polyols
• Propylene glycol, subject to irritation and residue assessment
• Low-level panthenol
• Selected water-compatible emollient systems
• Mild amphiphilic agents that improve wetting without reducing chlorhexidine activity

The principal technical risk is that a humectant or emollient can increase drying time. A slower-drying product may reduce operating-room throughput, increase fire risk before ignition sources are removed, and weaken the product’s commercial differentiation.

Wetting and spreading agents

A small amount of a compatible wetting agent may improve coverage on hair-bearing or irregular skin. The candidate must not bind chlorhexidine, reduce its free concentration, or increase irritation.

Cationic, anionic, and strongly complexing excipients require particular caution. Chlorhexidine can interact with anionic materials and certain polymers. A formulation that creates an insoluble salt, reduces antimicrobial availability, or produces visible residue would be commercially inferior.

Colorants

A colorant can help clinicians verify coverage, particularly when the liquid is clear and applied over large surgical fields. The commercial value is operational rather than pharmacological. The risks are staining, allergy claims, impurity qualification, and different regulatory treatment across jurisdictions.

A colorant strategy is strongest when it delivers temporary visibility and disappears after drying or cleansing. Permanent staining would reduce acceptance in visible anatomical areas and may create a perception of poor product quality.

Film-forming excipients

Film-forming systems could extend residual activity or improve protection after application. They also create significant disadvantages:

• Longer drying time
• Greater residue
• Potential interference with surgical adhesives
• Higher risk of flammability before full drying
• More complicated extractables and leachables testing
• More difficult scale-up and cleaning validation

Film-forming technology may be commercially attractive for specialized use cases, but it is a poor fit for a direct substitute intended to compete with the established SoluPrep S presentation.

How should an excipient strategy be designed for SoluPrep S?

The optimal formulation program should rank excipients by measurable product attributes rather than by ingredient novelty.

Development objective	Preferred formulation approach	Main barrier
Preserve fast drying	Maintain high alcohol fraction and low nonvolatile solids	Skin dryness and irritation
Improve skin feel	Add low-level compatible humectant	Slower drying and residue
Improve coverage	Use controlled wetting system or applicator geometry	Chlorhexidine compatibility
Reduce staining	Use no colorant or a temporary color system	Coverage verification
Reduce odor	Modify applicator and package headspace	Alcohol concentration cannot be materially reduced without efficacy impact
Improve sustainability	Reduce plastic, optimize dose, use recyclable components	Sterility and chemical compatibility
Extend shelf life	Improve closure, oxygen control, and packaging barrier	Cost and recyclability
Reduce packaging waste	Use lower-material applicator architecture	Dose uniformity and user acceptance

The first development screen should test:

1. Chlorhexidine assay and related substances.
2. Isopropyl alcohol concentration.
3. Antimicrobial effectiveness.
4. Drying time.
5. Wetting and coverage.
6. Skin irritation and sensitization.
7. Residue after drying.
8. Applicator dose delivery.
9. Package compatibility.
10. Flammability and ignition safety.

A candidate that improves skin feel but materially increases drying time is unlikely to be commercially attractive. A candidate that improves coverage but interacts with chlorhexidine may fail before clinical evaluation.

What formulations could be protected by new patents?

The base composition is likely to face substantial prior-art pressure because hydroalcoholic chlorhexidine preparations are established products. New patent value is more likely to arise from a narrow combination of formulation, delivery, and performance limitations.

Formulation patent opportunities

Potential claim areas include:

• A defined 2% chlorhexidine gluconate and 70% isopropyl alcohol composition with a specified humectant range.
• A composition with reduced nonvolatile residue after a defined drying period.
• A formulation that maintains antimicrobial activity after addition of a skin-conditioning excipient.
• A low-irritation formulation with specified pH, osmolality, and free-chlorhexidine profile.
• A composition with a temporary visual indicator that changes color after adequate coverage or drying.
• A formulation that improves compatibility with surgical adhesives.
• A formulation with reduced crystallization or precipitation during long-term storage.
• A low-odor formulation that preserves the required alcohol concentration.

Patent claims should be tied to objective performance data. Generic claims to “a chlorhexidine and alcohol composition” are vulnerable to earlier disclosures and obviousness attacks.

Applicator and device patent opportunities

The delivery system may offer stronger protection than the liquid composition. Relevant claim areas include:

• Metered delivery of a defined liquid volume.
• Applicator heads that reduce pooling in skin folds.
• Flow-control systems that prevent over-application.
• Applicator geometry that improves coverage with one pass.
• Dual-compartment designs for separately stored components.
• Applicators that reduce contamination after opening.
• Packaging that prevents alcohol evaporation.
• Packaging compatible with sterilization and transport.
• Visual indicators for adequate wetting and drying.
• Low-plastic or recyclable applicator designs.

Device claims can create a practical barrier even when the liquid composition is difficult to protect. They also support lifecycle management without changing the active concentrations.

What is the Orange Book status of 3M SoluPrep S?

SoluPrep S is generally positioned as a topical antiseptic rather than a new molecular drug. Its Orange Book relevance is therefore limited compared with an NDA-approved prescription medicine.

Regulatory issue	SoluPrep S implication
Orange Book listing	No clear basis for treating the product as an Orange Book-listed innovative prescription drug
Generic pathway	Depends on the applicable OTC, monograph, abbreviated application, or national pathway
Drug-device combination	Applicator performance may require separate device and combination-product assessment
Patent certification	A Paragraph IV challenge is relevant only if an applicable listed patent exists for the approved reference product
Label protection	Method-of-use and safety labeling may constrain competitive claims even without Orange Book patents
Regulatory reference	Product-specific status must be assessed in the target jurisdiction

A competitor should not assume that the absence of a conventional Orange Book patent listing eliminates market barriers. Manufacturing controls, product-specific data, applicator design, trademarks, procurement contracts, and regulatory documentation can remain relevant.

When does SoluPrep S lose exclusivity?

SoluPrep S does not have a single conventional loss-of-exclusivity date comparable to a patented small-molecule prescription drug. Market entry depends on several overlapping protections:

• Any enforceable composition or formulation patents.
• Applicator and packaging patents.
• Regulatory exclusivity, if granted in the relevant jurisdiction.
• Brand recognition and hospital purchasing contracts.
• Manufacturing know-how.
• Product registration and technical documentation.
• Sterility, stability, and transport validation.

For a hydroalcoholic chlorhexidine product, the composition itself may be difficult to defend broadly. The most durable commercial protection is likely to come from the combination of reliable antimicrobial performance, applicator ergonomics, supply consistency, and hospital adoption.

Are Paragraph IV challenges likely for SoluPrep S?

A Paragraph IV challenge would require an Orange Book-listed patent covering the relevant approved product and a competitor filing an abbreviated application that certifies the patent is invalid, unenforceable, or not infringed. That structure is more typical for prescription products with listed patents than for a topical surgical antiseptic.

Potential litigation triggers would include:

• A newly issued formulation patent.
• A patent covering a particular unit-dose applicator.
• A patent covering a color-changing or coverage-verification system.
• A listed method-of-use patent tied to a specific surgical procedure.
• A patent covering a sterile manufacturing or packaging configuration.

The more likely competitive pathway is a non-infringing product with the same active concentrations but a different applicator, package, color system, or excipient profile.

What patent litigation affects SoluPrep S?

Public product information does not establish a product-specific SoluPrep S litigation schedule, settlement agreement, or Paragraph IV case that can be reliably attributed to the base formulation. The relevant litigation risk is more likely to arise from adjacent intellectual property covering chlorhexidine compositions, antiseptic applicators, sterile packaging, and surgical skin-preparation methods.

A freedom-to-operate review should separate four patent groups:

1. Chlorhexidine-alcohol compositions.
2. Single-use applicators and dose-control systems.
3. Sterile packaging and evaporation-control systems.
4. Surgical preparation methods and clinical-use protocols.

Method-of-use claims may be narrower than composition claims but can still affect hospital-focused commercialization. They are most relevant where the product is promoted for a specific procedure, patient population, or infection-prevention protocol.

What manufacturing and IP barriers affect commercial entry?

The formulation is relatively simple. Manufacturing and quality-control execution are not.

Manufacturing barriers

Key manufacturing requirements include:

• Accurate blending of volatile alcohol with the aqueous phase.
• Control of chlorhexidine concentration and pH.
• Prevention of precipitation or adsorption.
• Control of alcohol evaporation during filling.
• Compatibility with high-barrier containers.
• Sterility or bioburden control, depending on product presentation.
• Consistent applicator fill volume.
• Validation of drying and delivery performance.
• Transport testing for leakage, pressure, and temperature exposure.

The alcohol component creates flammability and facility-design requirements. Packaging components must resist swelling, stress cracking, extractables, and seal failure.

Intellectual-property barriers

The main IP barriers are unlikely to be limited to the active ingredients. They may include:

• Applicator construction.
• Dose metering.
• Sponge or pad material.
• Sterile barrier design.
• Packaging headspace control.
• Colorant systems.
• Low-residue or low-irritation compositions.
• Use with surgical drapes and adhesives.
• Manufacturing methods that preserve alcohol concentration.

A competitor can reduce risk by using a distinct applicator architecture, avoiding protected color systems, and designing a formulation around independently supported excipient choices.

Which commercial opportunities exist beyond the base SoluPrep S product?

Hospital and operating-room segment

The largest near-term opportunity is an equivalent or improved product for hospitals that want:

• Lower acquisition cost.
• Reliable supply.
• Faster drying.
• Reduced skin irritation.
• Better coverage visibility.
• Lower packaging waste.
• Compatibility with surgical adhesives and drapes.

Hospitals may value applicator consistency as much as the liquid formulation. A product that reduces preparation time or avoids repeat application can support premium pricing even when the active concentrations are identical.

Sensitive-skin and repeated-use segment

A lower-irritation version could target patients with fragile skin and healthcare workers exposed to repeated antiseptic use. The formulation must preserve the surgical antisepsis profile and avoid introducing a clinically meaningful delay in drying.

Pediatric and neonatal segment

This segment carries higher safety scrutiny. Alcohol exposure, skin absorption, and ocular risk are central considerations. A separate product strategy may be needed rather than a simple excipient modification of SoluPrep S.

Sustainability segment

Commercial differentiation may come from:

• Reduced applicator mass.
• Recyclable outer packaging.
• Lower secondary packaging.
• Lower transport weight.
• Reduced alcohol evaporation during storage.
• Component designs that improve material recovery.

Environmental claims must be supported by validated lifecycle data. Recyclability alone will not overcome poor dose control or leakage performance.

Geographic expansion

The product can support regional line extensions through:

• Country-specific applicator sizes.
• Local language and warning labels.
• Different colorant policies.
• Local sterility and registration requirements.
• Market-specific packaging formats.
• Hospital tender presentations.

The active concentrations may remain constant while the package, applicator, and labeling are adapted to local regulatory and procurement requirements.

How does SoluPrep S compare with competing chlorhexidine skin preparations?

Attribute	SoluPrep S	Generic chlorhexidine-alcohol competitor	Povidone-iodine preparation
Primary antimicrobial system	Chlorhexidine plus isopropyl alcohol	Usually the same or similar	Iodine-based
Residual activity	Chlorhexidine provides residual activity	Depends on chlorhexidine formulation	Generally less persistent
Drying speed	High because of alcohol	Usually high	Often slower
Excipient flexibility	Limited by alcohol and chlorhexidine compatibility	Similar constraints	Broader but different compatibility issues
Main differentiation	Applicator, coverage, tolerability, supply	Price and delivery system	Iodine tolerance, indication, and clinical preference
Key risk	Flammability and irritation	Bioequivalence or performance equivalence	Allergy, staining, slower drying, and clinical preference

The strongest generic strategy is not to copy the brand presentation exactly. It is to match the active system while improving one operational metric that procurement teams can measure.

Key Takeaways

• 3M SoluPrep S is a topical surgical antiseptic, not a conventional prescription drug.
• Its core active system is 2% chlorhexidine gluconate in 70% isopropyl alcohol, with water as the principal vehicle.
• Excipient freedom is narrow because added materials can slow drying, increase residue, reduce chlorhexidine availability, or raise irritation risk.
• The strongest formulation opportunities involve low-level skin conditioning, improved wetting, temporary coverage visibility, and reduced residue.
• Applicator, packaging, and dose-control patents may offer stronger protection than broad composition claims.
• SoluPrep S does not have a conventional single loss-of-exclusivity date based solely on the base formulation.
• Paragraph IV exposure is likely to be limited unless a product-specific Orange Book-listed patent exists.
• Commercial entry is most attractive through hospital tenders, lower-irritation variants, sustainable packaging, and improved applicator performance.
• Manufacturing control of alcohol concentration, package integrity, dose volume, and stability is a material barrier to reliable market entry.

Frequently Asked Questions

Is isopropyl alcohol an excipient in 3M SoluPrep S?

No. In the standard SoluPrep S antiseptic system, isopropyl alcohol is an active antimicrobial ingredient. Water is the principal vehicle. Any additional material, such as a colorant or humectant, would be evaluated as an excipient.

Can a competitor patent a 2% chlorhexidine and 70% alcohol formulation?

A broad claim to the known active combination would face substantial prior-art risk. A stronger patent position would require a specific excipient range, performance limitation, stability result, delivery system, or clinical-use feature.

What excipient can reduce alcohol-related skin dryness?

Low-level humectants or compatible skin-conditioning agents are the main candidates. Their concentration must be controlled because they can increase drying time, residue, and flammability risk before the product fully dries.

Can a color-changing SoluPrep S alternative receive patent protection?

Potentially. Protection would be stronger if the color system has a defined transition tied to coverage or drying and produces a demonstrated operational benefit. A generic colorant claim would be more vulnerable to prior art.

Is an alcohol-free SoluPrep S substitute commercially viable?

An alcohol-free product would be a distinct formulation and regulatory project. It may address flammability or tolerability concerns but would need to reproduce rapid antimicrobial performance, coverage, drying behavior, and residual activity through a different active and excipient system.

References

1. 3M Health Care. (n.d.). 3M SoluPrep surgical skin preparation: Product information and instructions for use. 3M Company.

2. U.S. Food and Drug Administration. (2017). Safety and effectiveness of health care antiseptics: Topical antimicrobial drug products for over-the-counter human use. Federal Register, 82 Fed. Reg. 60474.

3. U.S. Food and Drug Administration. (2016). Safety and effectiveness of health care antiseptics: Topical antimicrobial drug products for nonprescription human use. Federal Register, 81 Fed. Reg. 61106.

4. U.S. Pharmacopeial Convention. (2023). United States Pharmacopeia and National Formulary: General chapters on antimicrobial effectiveness, packaging, and pharmaceutical compounding. United States Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.